+

WO2012030308A3 - Formulation comprenant la cellobiose - Google Patents

Formulation comprenant la cellobiose Download PDF

Info

Publication number
WO2012030308A3
WO2012030308A3 PCT/TR2011/000198 TR2011000198W WO2012030308A3 WO 2012030308 A3 WO2012030308 A3 WO 2012030308A3 TR 2011000198 W TR2011000198 W TR 2011000198W WO 2012030308 A3 WO2012030308 A3 WO 2012030308A3
Authority
WO
WIPO (PCT)
Prior art keywords
cellobiose
formulation
copd
asthma
carrier
Prior art date
Application number
PCT/TR2011/000198
Other languages
English (en)
Other versions
WO2012030308A2 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11776267.4A priority Critical patent/EP2611431A2/fr
Publication of WO2012030308A2 publication Critical patent/WO2012030308A2/fr
Publication of WO2012030308A3 publication Critical patent/WO2012030308A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique, comprenant un excipient et un ou plusieurs agents actifs, qui a été développée pour être utilisée dans le traitement des maladies des voies respiratoires telles que l'asthme et la BPCO.
PCT/TR2011/000198 2010-09-01 2011-08-24 Formulation comprenant la cellobiose WO2012030308A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11776267.4A EP2611431A2 (fr) 2010-09-01 2011-08-24 Formulation comprenant la cellobiose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07250 2010-09-01
TR2010/07250A TR201007250A2 (tr) 2010-09-01 2010-09-01 Selobioz içeren formülasyon.

Publications (2)

Publication Number Publication Date
WO2012030308A2 WO2012030308A2 (fr) 2012-03-08
WO2012030308A3 true WO2012030308A3 (fr) 2012-08-09

Family

ID=44883366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000198 WO2012030308A2 (fr) 2010-09-01 2011-08-24 Formulation comprenant la cellobiose

Country Status (3)

Country Link
EP (1) EP2611431A2 (fr)
TR (1) TR201007250A2 (fr)
WO (1) WO2012030308A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007766A1 (fr) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalateurs de poudre sèche comprenant un excipient autre que le lactose
WO2014007771A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
EP3247403A1 (fr) 2015-01-22 2017-11-29 Pfeifer & Langen GmbH & Co. KG Cellobiose contenue dans des compositions à consommer ou à prendre par voie orale
IT201900008340A1 (it) * 2019-06-07 2020-12-07 Genetic S P A Sali di montelukast e loro composizioni farmaceutiche

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089491A1 (fr) * 2000-05-19 2001-11-29 Astrazeneca Ab Nouveau procede
US6482429B1 (en) * 2001-06-20 2002-11-19 Boehringer Ingelheim Pharmaceuticals, Inc. Stable powder inhalation dosage formulation
WO2003088944A1 (fr) * 2002-04-13 2003-10-30 Glaxo Group Limited Composition de poudre seche a inhaler
WO2005004853A1 (fr) * 2003-07-08 2005-01-20 Aventis Pharma Limited Poudre seche pour inhalation comprenant un sel formoterol et du ciclesonide
WO2005004846A1 (fr) * 2003-07-11 2005-01-20 Glaxo Group Limited Formulations pharmaceutiques inhalables contenant un ester de sucre
US20060147537A1 (en) * 2003-05-28 2006-07-06 Sanofi-Aventis Pharma Limited Stabilized pharmaceutical product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089491A1 (fr) * 2000-05-19 2001-11-29 Astrazeneca Ab Nouveau procede
US6482429B1 (en) * 2001-06-20 2002-11-19 Boehringer Ingelheim Pharmaceuticals, Inc. Stable powder inhalation dosage formulation
WO2003088944A1 (fr) * 2002-04-13 2003-10-30 Glaxo Group Limited Composition de poudre seche a inhaler
US20060147537A1 (en) * 2003-05-28 2006-07-06 Sanofi-Aventis Pharma Limited Stabilized pharmaceutical product
WO2005004853A1 (fr) * 2003-07-08 2005-01-20 Aventis Pharma Limited Poudre seche pour inhalation comprenant un sel formoterol et du ciclesonide
WO2005004846A1 (fr) * 2003-07-11 2005-01-20 Glaxo Group Limited Formulations pharmaceutiques inhalables contenant un ester de sucre

Also Published As

Publication number Publication date
WO2012030308A2 (fr) 2012-03-08
TR201007250A2 (tr) 2012-03-21
EP2611431A2 (fr) 2013-07-10

Similar Documents

Publication Publication Date Title
WO2012016889A3 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2011099832A3 (fr) Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
IL217572A (en) 3,1-Propanedisulfonic Acids
WO2012177757A3 (fr) Compositions de soin personnel comprenant des particules abrasives formées
IL221940A (en) Small anti-infective compounds, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of bacterial infections
WO2012098562A3 (fr) Compositions liquides pour administration par voie orale de sels de lanthane
EP2776059A4 (fr) Compositions pharmaceutiques contenant des protéases et procédés pour le traitement de maladies liées au stockage lysosomal
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
WO2014016548A3 (fr) Composition pharmaceutique
WO2011076842A3 (fr) Préparation aérosol pour copd (bronchopneumopathie chronique obstructive)
WO2014007972A3 (fr) Nanoparticules d'épinéphrine, procédé pour les fabriquer et procédés pour les utiliser pour le traitement d'affections répondant à l'épinéphrine
WO2011152804A3 (fr) Procédé pour formulations pulvérulentes sèches
WO2012030308A3 (fr) Formulation comprenant la cellobiose
WO2014064652A3 (fr) Composition pharmaceutique stable d'interféron pégylé alpha-2b
WO2011076840A3 (fr) Préparation aérosol pour bronchopneumopathie chronique obstructive
WO2011093818A3 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
WO2012093973A3 (fr) Formulations stables d'acarbose
WO2011093815A3 (fr) Compositions pharmaceutiques comprenant du formotérol et du mométasone
WO2012064302A3 (fr) Préparations de montélukast améliorées
WO2011139249A3 (fr) Composition pharmaceutique renfermant du cefdinir
WO2011093831A3 (fr) Formulations effervescentes contenant du cefprosil comme principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11776267

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011776267

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载